Five of top 20 drug introductions target cancer, reflecting its rising incidence in India
Earnings per share excluding some items surged to $2.09, Astra said Thursday, higher than the $2.04 estimated by analysts surveyed by Bloomberg
The decision to ditch the development of an existing facility in the Speke area of Liverpool comes at a time when Prime Minister Keir Starmer is pushing hard to drum up investment in Britain
AstraZeneca share rose after it that the company has secured permission to import pharmaceutical formulations of new drug for sale or for distribution in Form CT-20 from CDSCO
Two late-stage studies published Wednesday in The Lancet show that Astra's Imfinzi and Merck's Keytruda delayed the progress of liver cancer when combined with other drugs and a local treatment
Global portfolio includes over 20 novel therapies; development follows reports of layoffs affecting over 125 employees within the unit
Feedback from the EU indicated that the trial results, which the application was based on, showed that the drug did not significantly improve overall survival for patients
Doing business in China had become tougher for five consecutive years and only 41 per cent of its members were expecting to have a better time next year, the survey said
The researchers found that Fasenra can be more effective than the oral corticosteroid prednisolone when injected during an attack, also called an exacerbation, which can involve symptoms such
The Central Drugs Standard Control Organisation granted approval for the drug's use in combination with Durvalumab for the maintenance treatment of advanced or recurrent endometrial cancer in adults
This approval establishes the use of Olaparib in combination with Durvalumab as a maintenance treatment for adult patients with advanced or recurrent endometrial cancer, said AstraZeneca Pharma
Shares of AstraZeneca Pharma India rose 2.98 per cent at Rs 6,588.35 per share on the BSE in Tuesday's intraday deals
AstraZeneca Pharma India on Wednesday said its net profit declined by 27 per cent on-year to Rs 38 crore in the second quarter ended on September 30, 2024. The drug firm reported a net profit of Rs 52 crore in the July-September quarter of last fiscal. Revenue from operations stood at Rs 408 crore for the period under review compared with Rs 311 crore in the year-ago period, the firm said in a regulatory filing. Shares of the company ended 3.74 per cent lower at Rs 7,133.10 apiece on the BSE.
AstraZeneca now expects 2024 revenue and core earnings per share to grow by a high-teens percentage, from a previous forecast of a mid-teens percentage at constant currency rates for both revenue
Biz of making films and shows needs more such tie-ups if it is to scale up
The Global Innovation and Technology Centre (GITC) in Chennai will be hiring around 1,300 people in the next 18 months, while another 900 will be hired in Bengaluru
AstraZeneca Pharma India Managing Director and Country President, Sanjeev Panchal, talks to Shine Jacob about the company's future plans in an interview
The receipt of this permission paves way for the launch of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion (Imfinzi) in India
The uptick in AstraZeneca share price came after the company announced that it has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL sol from CDSO.
The overall survival, or OS rates, in the TROPION-Breast01 Phase III trial of datopotamab deruxtecan (Dato-DXd), did not achieve statistical significance